Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients
1 other identifier
interventional
50
1 country
1
Brief Summary
Anhedonia, i.e., reduced positive mood and decreased sensitivity to rewards, is observed in many psychiatric illnesses, particularly depression and anxiety disorders. Untreated anhedonia predicts worse clinical outcomes and poorer response to treatment, yet cognitive behavioral treatment approaches to target anhedonia are fraught with poor patient compliance in real-life settings. The proposed study aims to address this gap by 1) testing the usefulness of a non-invasive, computationally informed, cognitive training in boosting reward sensitivity and reducing anhedonia in depressed and anxious patients, and 2) delineating the neurocomputational mechanisms of change associated with such intervention. In other words, can we train the brain to obtain rewards and boost positive mood among depressed and anxious individuals? This project will help to develop a computational training protocol aimed at reducing anhedonia and improving existing interventions for psychiatric conditions characterized by reward processing deficits. Long-term goals include expanding this framework to a broader range of appetitive and social stimuli to develop precise cognitive training tools to treat anhedonia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 16, 2022
CompletedFirst Posted
Study publicly available on registry
May 20, 2022
CompletedStudy Start
First participant enrolled
September 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 16, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 16, 2023
CompletedNovember 29, 2023
November 1, 2023
1.2 years
May 16, 2022
November 28, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
Reward Maximization
Individually fitted computational parameter of reward maximization strategy during the reward learning task
Change between Pre-Training and Post-Training Assessments (about 20 min)
Positive Affect
State positive affect measured with the Positive and Negative Affect Schedule (PANAS)
Change between Pre-Training and Post-Training Assessments (about 20 min)
Neural Tracking of Reward Expectation
Neural activity, i.e., blood oxygen level dependent (BOLD) response, in the striatum and medial prefrontal cortex correlating with participants' trial-level model-based reward expectations and associated prediction errors during the Reward Learning Task
Change between Pre-Training and Post-Training Assessments (about 20 min)
Study Arms (2)
High Reward - High Variance
EXPERIMENTALHigh Reward - Low Variance
ACTIVE COMPARATORInterventions
Computerized reward learning task designed to increase reward responsiveness
Computerized reward learning task designed to have minimal effect on reward responsiveness
Eligibility Criteria
You may qualify if:
- Age 18-65 (all races, both males and females will be included)
- Current diagnosis of Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)
- A score \< 7 on the Snaith-Hamilton Pleasure Scale (SHAPS) or \< 25 on the Positive Affect subscale from the Positive And Negative Affect Scale (PANAS)
- Sufficient proficiency in English language to understand and complete informed consent, interviews, questionnaires, and all other study procedures.
- Having normal or corrected vision
- Having normal or corrected hearing
You may not qualify if:
- Endorsement of past or current psychotic or bipolar disorder.
- Endorsement of recent severe alcohol or substance use disorder (past 3 months).
- Inability to discontinue for 48 hours prior to scan any medications incompatible with measuring reliable/interpretable neural activity (e.g., e.g., benzodiazepines/beta-blockers, atypical anti-depressants, anxiolytics and sedative hypnotics, antipsychotics, and opioid analgesics)
- Being unsafe to undergo functional magnetic resonance imaging (fMRI), i.e., being pregnant, presence of non-removable metal in body, medical conditions that are incompatible with safe MRI (e.g., claustrophobia, inability to lie still on one's back for approximately 60 minutes; prior neurosurgery)
- Clinical conditions assessed by the interviewer that necessitate more imminent clinical care (e.g., active suicidal ideation): These criteria are in place so participants with these other, more several symptoms can be referred for appropriate mental health services.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCSD Center for Functional Magnetic Resonance Imaging
La Jolla, California, 92093, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Clinical Professor
Study Record Dates
First Submitted
May 16, 2022
First Posted
May 20, 2022
Study Start
September 14, 2022
Primary Completion
November 16, 2023
Study Completion
November 16, 2023
Last Updated
November 29, 2023
Record last verified: 2023-11